Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study

Sarah F. Adams, Phyllis A. Gimotty, Teresa L. Rutledge, David M. O’Malley, Kari Ring, Robert M. Wenham, Karen Finkelstein, Elizabeth Lokich, Daniel M. Falcon, Alyson Yeckes, Olufunmilola M. Oyebamiji, Kathryn J. Brayer, Eleanor Paskus, Nadja K. Falk, Ryland Richards, Ji-Hyun Lee, Steven C. Eberhardt, Dennis McCance, Xavier Paliard, Sean Boyle, Richard Chen, Huining Kang, Jose R. Conejo-Garcia, Olivier Rixe, Carolyn Y. Muller

Open source

DOI: 10.1038/s41467-026-78395-y
Published: 2026-10-08
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-78395-y,
  title = {Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study},
  author = {Sarah F. Adams and Phyllis A. Gimotty and Teresa L. Rutledge and David M. O’Malley and Kari Ring and Robert M. Wenham and Karen Finkelstein and Elizabeth Lokich and Daniel M. Falcon and Alyson Yeckes and Olufunmilola M. Oyebamiji and Kathryn J. Brayer and Eleanor Paskus and Nadja K. Falk and Ryland Richards and Ji-Hyun Lee and Steven C. Eberhardt and Dennis McCance and Xavier Paliard and Sean Boyle and Richard Chen and Huining Kang and Jose R. Conejo-Garcia and Olivier Rixe and Carolyn Y. Muller},
  year = {2026},
  journal = {Nature Communications},
  doi = {10.1038/s41467-026-78395-y},
  url = {https://doi.org/10.1038/s41467-026-78395-y}
}

RIS

TY  - JOUR
TI  - Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
AU  - Sarah F. Adams
AU  - Phyllis A. Gimotty
AU  - Teresa L. Rutledge
AU  - David M. O’Malley
AU  - Kari Ring
AU  - Robert M. Wenham
AU  - Karen Finkelstein
AU  - Elizabeth Lokich
AU  - Daniel M. Falcon
AU  - Alyson Yeckes
AU  - Olufunmilola M. Oyebamiji
AU  - Kathryn J. Brayer
AU  - Eleanor Paskus
AU  - Nadja K. Falk
AU  - Ryland Richards
AU  - Ji-Hyun Lee
AU  - Steven C. Eberhardt
AU  - Dennis McCance
AU  - Xavier Paliard
AU  - Sean Boyle
AU  - Richard Chen
AU  - Huining Kang
AU  - Jose R. Conejo-Garcia
AU  - Olivier Rixe
AU  - Carolyn Y. Muller
PY  - 2026
JO  - Nature Communications
DO  - 10.1038/s41467-026-78395-y
UR  - https://doi.org/10.1038/s41467-026-78395-y
ER  -

APA

Adams, S. F., Gimotty, P. A., Rutledge, T. L., O’Malley, D. M., Ring, K., Wenham, R. M., Finkelstein, K., Lokich, E., Falcon, D. M., Yeckes, A., Oyebamiji, O. M., Brayer, K. J., Paskus, E., Falk, N. K., Richards, R., Lee, J., Eberhardt, S. C., McCance, D., Paliard, X., Boyle, S., Chen, R., Kang, H., Conejo-Garcia, J. R., Rixe, O., & Muller, C. Y. (2026). Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study. Nature Communications. https://doi.org/10.1038/s41467-026-78395-y

Source records

crossref · retrieved 2026-11-08T22:45:50.608Z